Simon Rizk, MD
Cardiovascular Disease · Pascagoula, MSNPI 1720092877
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (52.9%), food and beverage and education — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Angiodynamics, Inc. at 53.8% of the total. Reporting peaked in 2024 at $5,422 and has fallen 69.7% since, to $1,640 in 2025.
Across 339 payments — averaging $46.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$8K
- Boston Scientific$1K
- Johnson & Johnson$835
- Abiomed$744
- Merck$575
- AstraZeneca$478
- plus $3K from 27 others
What the payments were for
- Food & beverage$7,24046%
- Education$951%
- Gifts$750%
- Other$8,33353%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 4 | $8,474 |
| Boston Scientific | 37 | $1,257 |
| Johnson & Johnson | 44 | $835 |
| Abiomed | 27 | $744 |
| Merck | 27 | $575 |
| AstraZeneca | 30 | $478 |
| Medtronic(2 entities) | 19 | $440 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 21 | $344 |
| Boehringer Ingelheim | 19 | $337 |
| Abbott | 13 | $277 |
| Sanofi-aventis U.S. LLC | 10 | $223 |
| E.r. Squibb & Sons, L.L.C. | 14 | $209 |
| Esperion Therapeutics, Inc. | 11 | $205 |
| Novartis | 11 | $195 |
| Pfizer | 8 | $186 |
| Philips North America LLC | 7 | $150 |
| Chiesi USA, Inc. | 5 | $134 |
| Amgen | 7 | $91 |
| Biotronik Inc. | 5 | $87 |
| Bayer | 4 | $72 |
| Edwards Lifesciences | 1 | $65 |
| Heartflow, Inc. | 1 | $61 |
| Arbor Pharmaceuticals, Inc. | 4 | $60 |
| Lilly USA, LLC | 1 | $41 |
| Impulse Dynamics (USA) Inc. | 1 | $34 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $25 |
| Braemar Manufacturing, LLC | 1 | $24 |
| Stryker | 1 | $24 |
| EKOS Corporation | 1 | $22 |
| Penumbra, Inc. | 1 | $20 |
| Cardiovascular Systems Inc. | 1 | $19 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| Novo Nordisk | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,744 in reported general payments places this provider in the 80th percentile of 144 cardiovascular disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 601 | $530,780 |
| EntrestoSacubitril/Valsartan | 286 | $374,623 |
| XareltoRivaroxaban | 328 | $283,984 |
| JardianceEmpagliflozin | 185 | $220,136 |
| FarxigaDapagliflozin Propanediol | 66 | $75,674 |
| MultaqDronedarone Hcl | 57 | $56,723 |
| VerquvoVericiguat | 24 | $45,923 |
| NexlizetBempedoic Acid/Ezetimibe | 29 | $23,910 |
| Repatha SureclickEvolocumab | 31 | $21,840 |
| BrilintaTicagrelor | 35 | $18,941 |
| Metoprolol Succinate | 793 | $8,414 |
| Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine | 29 | $6,102 |
| Amiodarone Hcl | 167 | $3,562 |
| Ranolazine ErRanolazine | 35 | $3,063 |
| Nebivolol Hcl | 55 | $2,746 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $186 | $530,780601 claims |
| NovartisEntresto | $195 | $374,623286 claims |
| Johnson & JohnsonXarelto | $835 | $283,984328 claims |
| Boehringer IngelheimJardiance | $337 | $220,136185 claims |
| AstraZenecaFarxiga, Brilinta | $478 | $94,616101 claims |
| Sanofi-aventis U.S. LLCMultaq | $223 | $56,72357 claims |
| MerckVerquvo | $575 | $45,92324 claims |
| Esperion Therapeutics, Inc.Nexlizet | $205 | $23,91029 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 144 cardiovascular disease providers in Mississippi.
Other cardiovascular disease in Pascagoula
- Mahmoud ZayedPascagoula$103K
- Hugo QuintanaPascagoula$48K
- Ediz TasanPascagoula$42K
- William PassarelliPascagoula$15K
- Dharmesh PatelSouthaven$1.5M
- Barry BertoletTupelo$469K
- Donny StokesJackson$207K
- James BenslerJackson$64K
- Michael HallJackson$54K
- Lawrence LeaderHattiesburg$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.